Similar articles

• Introduction. New directions in anti-inflammatory therapy and pain management.

  Hochberg MC. Hochberg MC. Semin Arthritis Rheum. 2002 Dec;32(3 Suppl 1):1-3. doi: 10.1053/sarh.2002.37213. Semin Arthritis Rheum. 2002. PMID: 12528068 Review. No abstract available.
• [Clinical efficacy of xefocam and its effect on arterial pressure and heart rhythm variability in patients with rheumatoid arthritis in combination with arterial hypertension].

  Tsurko VV, Parnes EIa, Krasnosel'skiĭ MIa. Tsurko VV, et al. Ter Arkh. 2002;74(5):63-6. Ter Arkh. 2002. PMID: 12087911 Clinical Trial. Russian.
• The COX 2 selective inhibitors: what the newspapers have not told you.

  Simon LS. Simon LS. Bull NYU Hosp Jt Dis. 2007;65(3):229-41. Bull NYU Hosp Jt Dis. 2007. PMID: 17922675 Review. No abstract available.
• Interaction of indomethacin with felodipine and enalapril.

  Morgan T, Anderson A. Morgan T, et al. J Hypertens Suppl. 1993 Dec;11(5):S338-9. J Hypertens Suppl. 1993. PMID: 8158412 Clinical Trial. No abstract available.
• The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

  Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators. Sowers JR, et al. Arch Intern Med. 2005 Jan 24;165(2):161-8. doi: 10.1001/archinte.165.2.161. Arch Intern Med. 2005. PMID: 15668361 Clinical Trial.